GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » Beta

Myrexis (Myrexis) Beta : 2.08 (As of Apr. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Myrexis Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-27), Myrexis's Beta is 2.08.


Myrexis Beta Historical Data

The historical data trend for Myrexis's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis Beta Chart

Myrexis Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13
Beta
Get a 7-Day Free Trial - - 0.99 1.07 0.92

Myrexis Quarterly Data
Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 0.99 1.04 1.02 0.92

Competitive Comparison of Myrexis's Beta

For the Shell Companies subindustry, Myrexis's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myrexis's Beta Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Myrexis's Beta distribution charts can be found below:

* The bar in red indicates where Myrexis's Beta falls into.



Myrexis Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Myrexis  (OTCPK:MYRX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Myrexis Beta Related Terms

Thank you for viewing the detailed overview of Myrexis's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Myrexis (Myrexis) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020
Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.
Executives
Xstelos Corp. 10 percent owner 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe director 1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper director 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman director, officer: Chairman, President and CEO 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle director 320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska director, officer: Chief Operating Officer 749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer director, officer: President and CEO C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden director, officer: President and CEO 320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie officer: Chief Operating Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines